A Phase 3 Long-term Study of TAK-536 in Pediatric Patients 6 to Less Than 16 Years With Hypertension

NCT02791438 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

27

Enrollment

INDUSTRY

Sponsor class

Conditions

Pediatric Hypertension

Interventions

DRUG: Azilsartan
DRUG: Placebo

Sponsor

Takeda